Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC)

Mitchell, Patricia L.; Goldstein, D.; Michael, M.; Beale, Philip; Friedlander, Michael; Zalcberg, John; Clarke, S.; White, Sherrie

doi:10.1200/jco.2005.23.16_suppl.3581

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[88][89][90][91][92][93] Of course, patients should avoid the cold or protect themselves from it and avoid handling or ingesting cold food and drink. Dose reduction, prolonging the infusion time up to 6 hours, or holding the oxaliplatin after a set number of doses (for example, after 6 doses in the OPTIMOX regimen) might reduce the neuropathy.…”

Section: Oxaliplatin-induced Neuropathymentioning

confidence: 99%

“…Although there was initial interest in gabapentin, 95 a more recent study demonstrated no benefit when gabapentin was administered with FOLFOX (fluorouracil/leucovorin/oxaliplatin). 91 Scavenging free radicals is an appealing option, and small studies 96,97 have suggested amifostine might reduce the risk of chronic neuropathy, but larger studies are needed. A randomized study has demonstrated that another free radical scavenger, glutathione, when administered to patients receiving oxaliplatin and fluorouracil, reduced the number of patients (43% vs. 79%) experiencing peripheral neuropathy, and there was no apparent reduction in the response rate.…”

Section: Management Of Colon Cancermentioning

confidence: 99%

See 1 more Smart Citation

Supportive Care in the Management of Colon Cancer

Morse

2006

Supportive Cancer Therapy

View full text Add to dashboard Cite

Section: Oxaliplatin-induced Neuropathymentioning

confidence: 99%

Section: Management Of Colon Cancermentioning

confidence: 99%

Supportive Care in the Management of Colon Cancer

Morse

2006

Supportive Cancer Therapy

View full text Add to dashboard Cite

“…None of these studies have detected any significant benefit in reducing intensity of pain or sensory neuropathy (Wong et al, 2005). Gabapentine has been also evaluated as an agent for lowering the incidence and severity of oxaliplatin-induced CIPN, but this drug has failed to lower either (Mitchell et al, 2005). Carbamazepine antagonises the effect of oxaliplatin in experimental models with rat DG neurons incubated with this anticancer agent (Adelsberger et al, 2000).…”

Section: Anticonvulsants and Antidepressantsmentioning

confidence: 99%

Neuropathy Secondary to Chemotherapy: A Real Issue for Cancer Survivors

Cidon¹

2012

Basic Principles of Peripheral Nerve Disorders

View full text Add to dashboard Cite

Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis

Seretny

Currie

Sena

et al. 2014

Pain

1,159

813

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting from chemotherapy for cancer. Severe acute CIPN may require chemotherapy dose reduction or cessation. There is no effective CIPN prevention strategy; treatment of established chronic CIPN is limited, and the prevalence of CIPN is not known. Here we used a systematic review to identify studies reporting the prevalence of CIPN. We searched Embase, Medline, CAB Abstracts, CINAHL, PubMed central, Cochrane Library, and Web of Knowledge for relevant references and used random-effects meta-regression to estimate overall prevalence. We assessed study quality using the CONSORT and STROBE guidelines, and we report findings according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance. We provide a qualitative summary of factors reported to alter the risk of CIPN. We included 31 studies with data from 4179 patients in our analysis. CIPN prevalence was 68.1% (57.7-78.4) when measured in the first month after chemotherapy, 60.0% (36.4-81.6) at 3months and 30.0% (6.4-53.5) at 6months or more. Different chemotherapy drugs were associated with differences in CIPN prevalence, and there was some evidence of publication bias. Genetic risk factors were reported in 4 studies. Clinical risk factors, identified in 4 of 31 studies, included neuropathy at baseline, smoking, abnormal creatinine clearance, and specific sensory changes during chemotherapy. Although CIPN prevalence decreases with time, at 6months 30% of patients continue to suffer from CIPN. Routine CIPN surveillance during post-chemotherapy follow-up is needed. A number of genetic and clinical risk factors were identified that require further study.

show abstract

Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC)

Cited by 5 publications

References 0 publications

Supportive Care in the Management of Colon Cancer

Supportive Care in the Management of Colon Cancer

Neuropathy Secondary to Chemotherapy: A Real Issue for Cancer Survivors

Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis

Contact Info

Product

Resources

About